Cargando…

Hypercholesterolaemia screening in Type 1 diabetes: a difference of opinion

AIM: To assess cholesterol screening of children with Type 1 diabetes by diabetes professionals using a survey of current practice, given that National Institute of Health and Care Excellence guidelines on childhood Type 1 diabetes do not recommend cholesterol screening, yet the National Paediatric...

Descripción completa

Detalles Bibliográficos
Autores principales: Candler, T., Mahmoud, O., Edge, J., Hamilton‐Shield, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485173/
https://www.ncbi.nlm.nih.gov/pubmed/28144991
http://dx.doi.org/10.1111/dme.13322
_version_ 1783246008474402816
author Candler, T.
Mahmoud, O.
Edge, J.
Hamilton‐Shield, J.
author_facet Candler, T.
Mahmoud, O.
Edge, J.
Hamilton‐Shield, J.
author_sort Candler, T.
collection PubMed
description AIM: To assess cholesterol screening of children with Type 1 diabetes by diabetes professionals using a survey of current practice, given that National Institute of Health and Care Excellence guidelines on childhood Type 1 diabetes do not recommend cholesterol screening, yet the National Paediatric Diabetes Audit has an annual cholesterol measure (> 12 years) as a key outcome indicator. METHODS: An online survey was sent to 280 members of the Association of Children's Diabetes Clinicians to assess cholesterol screening practice in children. RESULTS: A total of 87 diabetes professionals (31%) responded. The results showed that 94% of respondents measured cholesterol, 33% did this annually on all children, and 7% measured fasting cholesterol. A total of 63% used no guidelines to decide treatment or further investigation. The definition of ‘high’ cholesterol varied from > 4.5 to > 8 mmol/l, with 40% giving no response or specific level. Only 14% of clinicians had started statin therapy in their diabetes clinic in the previous 5 years. CONCLUSION: Whilst the majority of diabetes professionals measured cholesterol in children with Type 1 diabetes, there was marked variability in sampling, in children screened and in action taken if levels were considered abnormal. It is debatable whether cholesterol measures should be undertaken, certainly more than once, and whether cholesterol level should feature as a key outcome in the national audit in future.
format Online
Article
Text
id pubmed-5485173
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54851732017-07-11 Hypercholesterolaemia screening in Type 1 diabetes: a difference of opinion Candler, T. Mahmoud, O. Edge, J. Hamilton‐Shield, J. Diabet Med Research Articles AIM: To assess cholesterol screening of children with Type 1 diabetes by diabetes professionals using a survey of current practice, given that National Institute of Health and Care Excellence guidelines on childhood Type 1 diabetes do not recommend cholesterol screening, yet the National Paediatric Diabetes Audit has an annual cholesterol measure (> 12 years) as a key outcome indicator. METHODS: An online survey was sent to 280 members of the Association of Children's Diabetes Clinicians to assess cholesterol screening practice in children. RESULTS: A total of 87 diabetes professionals (31%) responded. The results showed that 94% of respondents measured cholesterol, 33% did this annually on all children, and 7% measured fasting cholesterol. A total of 63% used no guidelines to decide treatment or further investigation. The definition of ‘high’ cholesterol varied from > 4.5 to > 8 mmol/l, with 40% giving no response or specific level. Only 14% of clinicians had started statin therapy in their diabetes clinic in the previous 5 years. CONCLUSION: Whilst the majority of diabetes professionals measured cholesterol in children with Type 1 diabetes, there was marked variability in sampling, in children screened and in action taken if levels were considered abnormal. It is debatable whether cholesterol measures should be undertaken, certainly more than once, and whether cholesterol level should feature as a key outcome in the national audit in future. John Wiley and Sons Inc. 2017-03-08 2017-07 /pmc/articles/PMC5485173/ /pubmed/28144991 http://dx.doi.org/10.1111/dme.13322 Text en © 2017 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Articles
Candler, T.
Mahmoud, O.
Edge, J.
Hamilton‐Shield, J.
Hypercholesterolaemia screening in Type 1 diabetes: a difference of opinion
title Hypercholesterolaemia screening in Type 1 diabetes: a difference of opinion
title_full Hypercholesterolaemia screening in Type 1 diabetes: a difference of opinion
title_fullStr Hypercholesterolaemia screening in Type 1 diabetes: a difference of opinion
title_full_unstemmed Hypercholesterolaemia screening in Type 1 diabetes: a difference of opinion
title_short Hypercholesterolaemia screening in Type 1 diabetes: a difference of opinion
title_sort hypercholesterolaemia screening in type 1 diabetes: a difference of opinion
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485173/
https://www.ncbi.nlm.nih.gov/pubmed/28144991
http://dx.doi.org/10.1111/dme.13322
work_keys_str_mv AT candlert hypercholesterolaemiascreeningintype1diabetesadifferenceofopinion
AT mahmoudo hypercholesterolaemiascreeningintype1diabetesadifferenceofopinion
AT edgej hypercholesterolaemiascreeningintype1diabetesadifferenceofopinion
AT hamiltonshieldj hypercholesterolaemiascreeningintype1diabetesadifferenceofopinion